Immune Tolerance Network for allergy, autoimmunity, and transplantation
Official title: Immune Tolerance Network
Funded at Benaroya Research Inst at Virginia Mason · NIH-11609232 · Data updated 2026-11-12
A large NIH program tests new immune-tolerance therapies to help people with autoimmune diseases, allergies, and transplant patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | February 1, 2014 |
| Project end | January 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,000,000 |
| NIH project number | 3UM1AI109565-13S3 |
| Project ID | NIH-11609232 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with autoimmune diseases, allergic diseases, or those awaiting or having had organ transplantation who meet trial eligibility criteria.
✕Less likely to help
Some patients may not respond to tolerance therapies or may experience adverse effects, limiting benefit.
What this research studies
This program runs high-quality clinical trials and combines them with advanced lab studies to understand how treatments shift the immune system. It spans multiple diseases to learn common and distinct immune mechanisms, aiming to speed up the availability of safer, more effective therapies. Researchers work with many clinical sites to test novel approaches and monitor cellular and genetic changes in patients receiving tolerance therapies. If successful, the work could lead to broader use of tolerance strategies across several immune-related conditions.
Why it matters
Potential benefit: If successful, people with autoimmune diseases, allergies, or transplant recipients could experience safer therapies that reduce rejection and improper immune responses.
How similar studies have gone: Previous tolerance studies have shown promise in informing immune modulation, but this program aims to accelerate broader and more durable options.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.